[A Survey to Compare the Specifications and Stability of Anticancer Drugs in Japan, the United States, Canada, and Australia].
Recently, expensive anticancer drugs such as molecularly targeted drugs have been reportedly ineffective. The use of drug vial optimization(DVO)has been proposed to overcome this problem. The specifications and stability of anticancer drugs in Japan were compared to those in other countries that used DVO, based on the results of the survey reported at the 2016 International Society of Oncology Pharmacy Practitioners meeting that compared the international specifications and stability of anticancer drugs. Our survey investigated expensive and frequently used anticancer drugs: 14 anticancer monoclonal anti- bodies(MABs)and 26 cytotoxic agents. About 29%(4/14)of the MABs and 54%(14/26)of the cytotoxic agents mar- keted in other countries were sold in larger vials than those marketed in Japan. About 67%(2/3)of theMABs and 38%(8/ 21)of the cytotoxic agents marketed in other countries had stability data of reconstitution obtained across longer test periods than those in Japan. About 29%(4/14)of theMABs and 50%(13/26)of the cytotoxic agents marketed in other countries had stability data of final dilution obtained across longer test periods than those in Japan. The stability data obtained in Japan were comparable to those obtained in 3 other countries that used DVO. However, some differences were noted in the specifications of anticancer drugs between Japan and other countries.